P-糖蛋白过表达介导的多药耐药与B细胞慢性淋巴细胞白血病中ZAP-70/CD38的表达无关。

Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.

作者信息

Guillaume Nicolas, Gouilleux-Gruart Valérie, Claisse Jean-François, Troussard Xavier, Lepelley Pascale, Damaj Gandhi, Royer Bruno, Garidi Reda, Lefrere Jean-Jacques

机构信息

Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Amiens, France.

出版信息

Leuk Lymphoma. 2007 Aug;48(8):1556-60. doi: 10.1080/10428190701457931.

DOI:10.1080/10428190701457931

PMID:17701587

Abstract

ZAP-70 and CD38 expression can identify B-cell chronic lymphocytic leukemia with an inferior clinical outcome. Many groups have investigated the meaning of the expression of these two proteins and the correlation with the bad prognosis in B-CLL. But nobody has investigated the relation between the multidrug resistance mediated by Pgp overexpression (MDR1) and ZAP-70/CD38 coexpression. Forty-one untreated and stage A patients, either ZAP-70(+)CD38(+) or ZAP-70(-)CD38(-), were tested to determine the MDR1 status. MDR1 was observed in 41% of CLL ZAP-70(+)CD38(+) and in 37% of CLL ZAP-70(-)CD38(-). The difference was not significant (p = 0.745). Patients with ZAP-70 and CD38 positive CLL can not be candidates for MDR1 antagonists.

摘要

ZAP-70和CD38表达可识别临床预后较差的B细胞慢性淋巴细胞白血病。许多研究小组已对这两种蛋白表达的意义以及与B-CLL不良预后的相关性进行了研究。但无人研究过由Pgp过表达介导的多药耐药性（MDR1）与ZAP-70/CD38共表达之间的关系。对41例未经治疗的A期患者进行检测，这些患者要么是ZAP-70(+)CD38(+)，要么是ZAP-70(-)CD38(-)，以确定其MDR1状态。在41%的ZAP-70(+)CD38(+) CLL患者和37%的ZAP-70(-)CD38(-) CLL患者中观察到MDR1。差异无统计学意义（p = 0.745）。ZAP-70和CD38呈阳性的CLL患者不能成为MDR1拮抗剂的候选对象。